What question did this study set out to answer?

To assess surgical management and outcomes in breast cancer patients undergoing neoadjuvant endocrine therapy.

February 19, 2026Clinical Cancer Research

Abstract RF1-02: Surgical outcomes in the ALTERNATE trial (Alliance A011106) -a randomized phase 3 neoadjuvant endocrine therapy (NET) trial in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC)

View Full Paper

Ask AI

Bookmark

To assess surgical management and outcomes in breast cancer patients undergoing neoadjuvant endocrine therapy.
Phase III randomized trial with postmenopausal women
Patients received anastrozole, fulvestrant, or both before surgery
Surgical procedures included sentinel lymph node biopsy and axillary lymph node dissection
Primary endpoint was pathologic complete response and evaluation of surgical eligibility for breast-conserving surgery
69.9% of patients underwent breast-conserving surgery after neoadjuvant treatment
43.8% of those initially deemed ineligible for breast-conserving surgery still underwent the procedure
The majority of patients with pathologic lymph node positivity had a lower burden of nodal involvement
Surgeons commonly applied standard surgical criteria for lymph node management after neoadjuvant treatment

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This phase III trial assesses surgical outcomes post-neoadjuvant endocrine therapy in postmenopausal women with ER+ HER2- breast cancer, suggesting new surgical approaches.

Cite This Study

Leitch et al. (2026) studied this question.

synapsesocial.com/papers/6996a887ecb39a600b3ef5a3 https://doi.org/10.1158/1557-3265.sabcs25-rf1-02

View Full Paper

Ask AI

Bookmark

Implication

This phase III trial assesses surgical outcomes post-neoadjuvant endocrine therapy in postmenopausal women with ER+ HER2- breast cancer, suggesting new surgical approaches.

Abstract RF1-02: Surgical outcomes in the ALTERNATE trial (Alliance A011106) -a randomized phase 3 neoadjuvant endocrine therapy (NET) trial in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC)

Key Points

Discussion

Implication

Cite This Study

Abstract RF1-02: Surgical outcomes in the ALTERNATE trial (Alliance A011106) -a randomized phase 3 neoadjuvant endocrine therapy (NET) trial in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider